Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Carboxylesterase family protein | 0.0164 | 0.9673 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0164 | 0.9673 | 0.9558 |
Loa Loa (eye worm) | carboxylesterase | 0.0164 | 0.9673 | 0.5 |
Schistosoma mansoni | alkaline phosphatase | 0.0167 | 1 | 1 |
Schistosoma mansoni | 23-cyclic-nucleotide 2-phosphodiesterase | 0.0143 | 0.7728 | 0.693 |
Echinococcus granulosus | alkaline phosphatase | 0.0167 | 1 | 1 |
Echinococcus multilocularis | intestinal type alkaline phosphatase | 0.0167 | 1 | 1 |
Echinococcus multilocularis | intestinal type alkaline phosphatase 1 | 0.0167 | 1 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0164 | 0.9673 | 0.5 |
Toxoplasma gondii | 5'-nucleotidase, C-terminal domain-containing protein | 0.0143 | 0.7728 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0164 | 0.9673 | 0.5 |
Echinococcus granulosus | intestinal type alkaline phosphatase 1 | 0.0167 | 1 | 1 |
Echinococcus multilocularis | alkaline phosphatase, intestinal, gene 2 | 0.0167 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0164 | 0.9673 | 0.5 |
Echinococcus multilocularis | alkaline phosphatase | 0.0167 | 1 | 1 |
Schistosoma mansoni | alkaline phosphatase | 0.0167 | 1 | 1 |
Echinococcus granulosus | alkaline phosphatase intestinal gene 2 | 0.0167 | 1 | 1 |
Treponema pallidum | 5'-nucleotidase (ushA) | 0.0143 | 0.7728 | 0.5 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0164 | 0.9673 | 0.5 |
Schistosoma mansoni | 23-cyclic-nucleotide 2-phosphodiesterase | 0.0142 | 0.769 | 0.6879 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (binding) | = 48.6 % | Inhibition of acetylcholinesterase (unknown origin) assessed as reduction in formation of 5-thio-2-nitrobenzoate from acetylthiocholine iodide at 5 ug/ml preincubated for 15 mins followed by substrate addition measured after 30 mins by Ellman's method | LITERATURE. | 27914796 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.